NCI BARDA U.S. Department of Defense FDA Office of Orphan Products Development
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib (Posted 12/22/2020)
21 Ha'arba'a Street Tel Aviv 6473921 Israel 972 3 541 3131 http://www.redhillbio.com [1] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1358&PID=0&IID=1899 [2] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=17299
PER IHUB MGMT
02-07-2021 DISCLAIMER: ONLY FOR MICK https://investorshub.advfn.com/boards/profilea.aspx?user=1012 *The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions, investments,decisions, or messages posted on this forum. CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING. ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN. ANY trade entered into risks the possibility of losing the funds invested. • There are no guarantees when buying or selling any security.Any
